Interesting links
Here are some interesting links for you! Enjoy your stay :)Pages
- A Targeted Metabolomics-Based Assay Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential
- About Stemina
- Application of the Biomarker-Based In Vitro Assays devTOX quickPredict and Cardio quickPredict for Toxicity Screening
- Archive
- Board of Directors
- Cardio quickPredict
- Careers
- Contact
- Custom Services
- Defining the Reproducibility and Applicability Domain of devTOX quickPredict, a Human Pluripotent Stem Cell-Based Developmental Toxicity Assay
- Developmental Computation with Embryonic Stem Cells
- devTOX quickPredict FAQs
- Home
- In Vitro to In Vivo Extrapolation for Developmental Toxicity Potency of Valproate Analogues
- Journal Publications
- Leadership
- Neurodevelopmental Division
- News
- Posters
- Predicting Developmental Toxicity Potential Using Pluripotent Embryonic Stem Cell Assays and the ToxCast Library
- Presentations
- Press Releases
- Privacy Policy
- Resources
- Scientific Advisory Board
- Upcoming Events
- Webinars
- devTox quickPredict
Categories
Archive
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- August 2021
- March 2021
- February 2021
- November 2020
- October 2020
- April 2020
- March 2020
- February 2020
- November 2019
- June 2019
- March 2019
- November 2018
- October 2018
- September 2018
- July 2018
- June 2018
- March 2018
- February 2018
- January 2018
- November 2017
- October 2017
- September 2017
- August 2017
- June 2017
- March 2017
- February 2017
- January 2017
- November 2016
- October 2016
- July 2016
- May 2016
- March 2016
- November 2015
- June 2015
- March 2015
- August 2014
- March 2014
- January 2014
- November 2013
- September 2013
- August 2013
- June 2013
- March 2013
- February 2013
- November 2012
- August 2012
- January 2012
- November 2011
- August 2010
- June 2010
- May 2010
- September 2009
- June 2009
- December 2007
devTOX quickPredictTM Accurately Predicts the Developmental Toxicity Potential of the ICH S5(R3) Guideline Reference Compounds [BDRP, 2022]
Presented by Jessica Palmer at the Society for Birth Defects and Research Meeting; June, 2022
There have been increased efforts in the pharmaceutical and chemical industries to incorporate new approach methods (NAMs) in vitro,, ex vivo, or in silico) earlier in the product development pipeline prior to in vivo testing.
devTOX quickPredictTM Accurately Predicts the Developmental Toxicity Potential of the ICH S5(R3) Guideline Reference Compounds [SOT, 2022]
Presented by Jessica Palmer at the Society for Toxicology Meeting; March, 2022
There have been increased efforts in the pharmaceutical and chemical industries to incorporate new approach methods (NAMs) (in vitro, ex vivo, or in silico) earlier in the product development pipeline prior to in vivo testing.
A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential [WC11, 2021]
Presented by Jessica Palmer at the 11th World Congress on Alternatives and Animal Use in the Life Sciences; August, 2021
Implementing screening assays that identify functional and structural cardiotoxicity earlier in the drug development pipeline has the potential to improve safety and the cost and time required to bring new drugs to market.
Defining the Reproducibility and Applicability Domain of devTOX quickPredictTM, a Human Pluripotent Stem Cell-Based Developmental Toxicity Assay [WC11, 2021]
Presented by Jessica Palmer at the 11th World Congress on Alternatives and Animal Use in the Life Sciences; August, 2021
Assessing the accuracy, reproducibility, and applicability domain of new approach methods (NAMs) is necessary step for establishing confidence in these methods and enabling their use in a regulatory setting.
A Human Pluripotent Stem Cell-Based Assay, devTOX quickPredictTM, Accurately and Reproducibly Predicts the Developmental Toxicity Potential Across a Diverse Set of Chemicals [SOT, 2021]
Presented by Jessica Palmer at the Society for Toxicology Meeting; March, 2021
Tyrosine kinase inhibitors (TKI) have greatly improved the treatment and prognosis for a wide range of cancers. Unfortunately, numerous TKIs produce cardiotoxic effects, which were not well predicted during preclinical studies.
In Vitro to In Vivo Extrapolation for Developmental Toxicity Potency of Valproic Acid Analogues [ASCCT, 2020]
Presented by Jessica Palmer at the American Society for Cellular and Computational Toxicology; October, 2020
Previous work showed that the potency ranking from devTOXqP assay was consistent with in vivo developmental toxicity potency, but whether the assay could quantitatively predict in vivo exposure exerting developmental toxicity was unknown.
Biomarker-Based Prediction of Tyrosine Kinase Inhibitor Cardiotoxicity using Human iPSC-Derived Cardiomyocytes [SPSM, 2019]
Presented by Jessica Palmer at the Safety Pharmacology Society Meeting in Barcelona, Spain; September, 2019
Tyrosine kinase inhibitors (TKI) have greatly improved the treatment and prognosis for a wide range of cancers. Unfortunately, numerous TKIs produce cardiotoxic effects, which were not well predicted during preclinical studies.
Developmental Toxicity Testing of Gaseous Chemicals with a Human Pluripotent Stem Cell-Based Assay [TSAM, 2019]
Presented at the Teratology Society Annual Meeting in San Diego, California; June 2019
Innovative in vitro toxicity screening assays aimed at reducing or replacing the use of animals in chemical safety testing are critical to meet the safety requirements across industries.
Next Generation Products Predicted to Have No Potential to Induce Developmental Toxicity in the devTOX quickPredictTM Assay [BTSAC, 2019]
Presented by Imperial Brands at the British Toxicology Society Annual Congress, in Cambridge, UK; April 2019
There is a growing scientific consensus that next generation products (NGPs) present a less harmful alternative to cigarettes for adult smokers. However, further research is required to adequately assess if NGP aerosols present a developmental risk to the unborn foetus.
Reproducibility and Applicability Domain of devTOX quickPredict, a Human Pluripotent Stem Cell-Based Developmental Toxicity Assay [FutureTox IV, 2018]
Presented at FutureTox IV, a Society of Toxicology (SOT) Contemporary Concepts in Toxicology (CCT) meeting, in Arlington, VA; November 2018.
The ICH recently release the draft S5(R3) Guideline on Detection of Toxicity to Reproduction for Human Pharmaceuticals, which outlines the use of new approach methods (NAMs) in certain circumstances and provides a framework for qualifying a NAM for regulatory acceptance. Part of this framework is to assess the accuracy, demonstrate reproducibility, and define the applicability domain of a NAM…
Prediction of Cardiotoxicity Potential Using Targeted Metabolomics and Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes [SPS, 2018]
Presented at the Safety Pharmacology Annual Meeting in Washington, DC; September/October 2018
Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for 28% if safety-related withdrawals of FDA-approved drugs from the market. Current cardiac safety preclinical evaluations are heavily focused on electrophysiological assessment and fail to evaluate cardiomyopathy and other forms of structural cardiotoxicity…
Human In Vitro Developmental Toxicity Assay Combined with a Read-Across Approach for Chemical Assessment [ASCCT, 2018]
Presented at the American Society for Cellular and Computational Toxicology; September 2018
The reproductive and developmental toxicity requirements for registering chemical substances under REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) using whole-animal models could cost up to $8 billion and require the use of up to 22 million animals…
A Human Pluripotent Stem Cell-Based Assay Accurately Predicts the Developmental Toxicity Potency for a Series of Valproate Analogues [Teratology Society, 2018]
Presented at the Teratology Society Annual Meeting in Clearwater, Florida; June 2018
Regulatory acceptance of alternative methods for toxicity testing remains a challenge despite international efforts to reduce animal use. Multiple agencies are working to develop a framework to implement the use of new approach methodologies for assessing the effects of chemical exposure on human health…
Applying Discovery Toxicology Approaches for Prediction of Developmental Phenotypes [Teratology Society, 2018]
Presented at the Teratology Society Annual Meeting in Clearwater, Florida; June 2018.
This poster was presented by toxicology professionals from Syngenta, Ltd. The research they discussed was conducted using Stemina’s assays.
The current in vivo tests to identify chemistries with developmental and reproductive toxicity (DART) hazards are resource-intensive, relatively slow, and as such, are often undertaken too late in product development to inform subsequent chemical design, should an effect be seen.
Development of an In Vitro Assay to Predict Cardiotoxicity Potential Using Targeted Metabolomics and Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes [SOT 2018]
Presented at the Society of Toxicology Annual Meeting and ToxEXPO in San Antonio, Texas, March 2018, by Stemina’s Associate Director of Toxicology, Jessica Palmer.
Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for 28% of the safety-related withdrawals of FDA-approved drugs from the market. Metabolic perturbations are one of the primary mechanisms of cardiotoxicity elicited by pharmaceuticals…
Development of a Targeted Biomarker Assay to Predict Cardiotoxicity Potential Using Metabolomics and Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes [ACT 2017]
Presented at the American College of Toxicology’s 38th Annual Meeting in Palm Springs, California in November 2017 by Stemina’s Associate Director of Toxicology, Jessica Palmer.
Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for 28% of the safety related withdrawals of FDA-approved drugs from the market…
EU-ToxRisk Case Study: Developmental Toxicity Potency of Valproate Analogues in Human Pluripotent Stem Cell-Based Assay [WC-10 (2017)]
Presented at the 10th World Congress on Alternatives and Animal Use in the Life Sciences in Seattle, August 2017, by Stemina’s Associate Director of Toxicology, Jessica Palmer.
The development and use of alternative models of safety screening in place of animal models has been at the forefront of the toxicology field for over a decade; however, application of these assays in a regular setting is still poorly understood…
Comparative Retrospective Analysis of In Vivo and In Vitro Developmental Toxicity Predictions [SOT 2017]
Presented at the Society of Toxicology’s Annual Meeting & ToxExpo in Baltimore, March 2017, by Stemina’s Associate Director of Toxicology, Jessica Palmer.
Development and validation of in vitro models for developmental toxicity testing is essential for reducing the number of animals used toxicity testing. These assays have the potential to reduce or replace animal use in chemical safety testing for multiple industries, as well as to support ongoing worldwide…